Eli Lilly has signed up CureVac to develop cancer vaccines based on its mRNA technology, in a deal that could potentially be worth more than $2.6 billion to the German
Eli Lilly has signed up CureVac to develop cancer vaccines based on its mRNA technology, in a deal that could potentially be worth more than $2.6 billion to the German